—

TELIX Pharmaceuticals Ltd (TLX.AU) — the peer cohort

As of 2026-11-21 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

TELIX Pharmaceuticals Ltd ranks 7 of 7 in its cohort on the Closelooknet composite (36/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
TLX.AU TELIX Pharmaceuticals Ltd 36 49 30 17 info 29.1%
HALO Halozyme Therapeutics Inc 72 68 94 50 info 31.8%
ONC BeOne Medicines AG 66 87 67 29 ok 8%
REGN Regeneron Pharmaceuticals Inc 65 90 72 47 neutral 7.2%
UCB.BR UCB SA 65 77 71 42 info 7.2%
ARGX.BR Argen-X 64 80 73 25 ok 7.8%
ARGX argenx NV ADR 63 71 73 25 ok 13.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-21

Quick answers

Who are TELIX Pharmaceuticals Ltd's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Regeneron Pharmaceuticals Inc (REGN), UCB SA (UCB.BR), Argen-X (ARGX.BR), argenx NV ADR (ARGX), as of 2026-11-21.

How does TLX.AU score against its peers?

TELIX Pharmaceuticals Ltd's composite reads 36/100, ranking 7 of 7 in its cohort as of 2026-11-21; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.